Werther M, Schmelz H-U, Schwerer M, Sparwasser C
Urologische Abteilung, Bundeswehrkrankenhaus, Oberer Eselsberg 40, 89081, Ulm, Germany.
Urologe A. 2007 Nov;46(11):1551-6. doi: 10.1007/s00120-007-1556-6.
Sertoli cell tumors of the testis are extremely rare (0.4-1.5% of all testicular neoplasms) and have a heterogeneous pathology. Histopathologically classic, large cell calcifying and sclerosing subtypes are differentiated.Up to now, 14 cases of sclerosing Sertoli cell tumor are known. This article presents a new case and compares the three subtypes. The subtypes differ in particular in age of onset, malignant potential, prognosis, and therapy. While no cases of sclerosing Sertoli cell tumor with a malignant course have been reported, both other subtypes have been found to be potentially malignant. In the case of malignancy the prognosis is very poor, and it is difficult to select the best treatment because there is so little experience with this type of tumor. Once the diagnosis of a Sertoli cell tumor has been confirmed, exact determination of the histological subtype is essential to allow appropriate risk-adapted therapy. The various histological subtypes are presented with the clinical features, prognosis and treatment of each.
睾丸支持细胞瘤极为罕见（占所有睾丸肿瘤的0.4 - 1.5%），且病理表现具有异质性。组织病理学上可区分出经典型、大细胞钙化型和硬化型亚型。截至目前，已知14例硬化型支持细胞瘤病例。本文报告1例新病例并比较这三种亚型。这些亚型在发病年龄、恶性潜能、预后及治疗方面存在差异。虽然尚未报道过硬化型支持细胞瘤出现恶性病程的病例，但已发现其他两种亚型具有潜在恶性。在恶性情况下，预后非常差，且由于对此类肿瘤的经验极少，难以选择最佳治疗方案。一旦支持细胞瘤的诊断得到证实，准确确定组织学亚型对于进行适当的风险适应性治疗至关重要。文中呈现了各种组织学亚型及其临床特征、预后和治疗情况。
